Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-Fi for Wounds in Dystrophic Epidermolysis Bullosa
NCT06892639Phase 3Active, not recruiting
- Sponsor
- Castle Creek Biosciences
- Start
- Mar 2025
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of dabocemagene autoficel in dystrophic epidermolysis bullosa (DEB) (2 arms), sponsored by Castle Creek Biosciences. Primary endpoint: Complete (100%) Wound Closure at 26 weeks. Started Mar 2025; status: active, not recruiting.
02
Drugs
dabocemagene autoficel
03
Conditions
dystrophic epidermolysis bullosa (DEB)
Beyond the preview
Go deeper on NCT06892639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06892639.